Leishmaniasis
is parasitic disease caused due to an infection with Leishmania
parasites and transmitted through the bite of infected female
phlebotomine sand flies. According to the World Health Organization
(WHO), approximately 7, 00,000 to 1 million new cases and 20,000 -
30,000 deaths occur worldwide annually due to the leishmaniasis.
There are three forms of leishmaniasis namely mucocutaneous
leishmaniasis, visceral leishmaniasis, and cutaneous leishmaniasis.
Visceral leishmaniasis (VL) is the most serious condition among the
other two forms of leishmaniasis. According to the World Health
Organization (WHO), about 50,000 to 90,000 new cases of visceral
leishmaniasis occur worldwide annually.
Download
PDF Brochure @
https://www.coherentmarketinsights.com/insight/request-pdf/932
According
to the WHO, in 2015, more than 90% of the new cases of visceral
leishmaniasis were from Kenya, Somalia, Ethiopia, India, Brazil,
Sudan, and South Sudan creating higher opportunity for leishmaniasis
treatment market. The prevalence of cutaneous leishmaniasis in the
North and South America, the Middle East, Central Asia, and
Mediterranean basin is approximately 95%, according to the WHO April
2017 factsheet. People with leishmaniasis infection develop several
symptoms, such as fever, weight loss, sores on skin, nose, mouth or
throat, enlargement of spleen and liver, and abnormal blood tests.
Some patients show symptoms of anemia, leukopenia, and
thrombocytopenia. Geriatric population, infants, pregnant or
lactating women, and HIV infected people have a high risk of
acquiring leishmaniasis infections, due to their weak immune systems.
Introduction
of new chemical entity will drive the leishmaniasis treatment market
According
to data published in 2017, by Drugs for Neglected Diseases initiative
(DNDi’), two new chemical entities (NCE) DNDI-6148 and DNDI-0690
are introduced into the preclinical development stage to treat
visceral and cutaneous leishmaniasis in 2016. Immunomodulator-
CpG-D35, is also in pre-clinical development stage, which will be
used as an adjunct along with drug therapy to fight cutaneous
leishmaniasis. These advances have the potential to transform drug
development into new treatment therapy in near future, in turn
driving the growth of leishmaniasis treatment market.
Combined
agreement between WHO and Gilead Sciences, Inc. will expand
leishmaniasis treatment market
In
2016, the World Health Organization (WHO) and Gilead Sciences, Inc.
signed an agreement to donate 3,80,400 vials of AmBisome (liposomal
amphotericin B), extending their previous agreement from 2016 to
2021. The five year collaboration and funding of US$ 20 million by
Gilead Sciences, Inc. are intended to provide access to diagnosis and
treatment to the populations affected by visceral leishmaniasis in
key endemic countries such as Ethiopia, India, Nepal, Bangladesh,
South Sudan, and Sudan. Financial contribution made by Gilead
Sciences, Inc. helped WHO to expand, control, and reinforce
surveillance in many endemic countries.
Key
Players in the Leishmaniasis treatment market
Key
players operating in the leishmaniasis treatment market include
Sanofi S.A., Sequus Pharmaceuticals Inc., Paladin Labs Inc., Enzon
Pharmaceuticals Inc., Gland Pharma Limited, and Lifecare Innovations
Private Limited.
Leishmaniasis
Treatment Market Taxonomy:
On
the basis of disease type, the leishmaniasis treatment market is
segmented into:
-
Cutaneous leishmaniasis
-
Visceral leishmaniasis
-
Mucocutaneous leishmaniasis
On
the basis of drug type, the leishmaniasis treatment market is
segmented into:
-
Pentavalent antimonials
-
Sodium stibogluconate
-
SSG Meglumine antimoniate
-
Antibiotics
-
Amphotericin B
-
Liposomal amphotericin B
-
Miltefosine
-
Paromomycin
-
Pentamidine
Browse
In-Depth Analysis Research Report @
https://www.coherentmarketinsights.com/ongoing-insight/leishmaniasis-treatment-market-932
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment